NASDAQ:ALLO - Allogene Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allogene Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.86 -1.22 (-6.08 %) (As of 03/31/2020 02:32 PM ET) Add Compare Today's Range$18.77Now: $18.86▼$20.1050-Day Range$18.22MA: $23.53▼$28.2552-Week Range$17.43Now: $18.86▼$33.80Volume38,014 shsAverage Volume824,360 shsMarket Capitalization$2.36 billionP/E RatioN/ADividend YieldN/ABeta0.53 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company was founded in 2017 and is headquartered in South San Francisco, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLO Previous Symbol CUSIPN/A CIKN/A Webhttp://www.allogene.com/ Phone650-457-2700Debt Debt-to-Equity Ratio0.08 Current Ratio16.46 Quick Ratio16.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book3.66Profitability EPS (Most Recent Fiscal Year)($1.83) Net Income$-184,590,000.00 Net MarginsN/A Return on Equity-28.56% Return on Assets-25.49%Miscellaneous Employees122 Outstanding Shares124,910,000Market Cap$2.36 billion Next Earnings Date5/5/2020 (Estimated) OptionableNot Optionable Receive ALLO News and Ratings via Email Sign-up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ALLO Rates by TradingView Allogene Therapeutics (NASDAQ:ALLO) Frequently Asked Questions How has Allogene Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Allogene Therapeutics' stock was trading at $25.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALLO shares have decreased by 24.7% and is now trading at $18.87. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Allogene Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allogene Therapeutics. When is Allogene Therapeutics' next earnings date? Allogene Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Allogene Therapeutics. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics Inc (NASDAQ:ALLO) issued its earnings results on Thursday, February, 27th. The company reported ($0.58) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.68) by $0.10. View Allogene Therapeutics' earnings history. What price target have analysts set for ALLO? 11 equities research analysts have issued twelve-month target prices for Allogene Therapeutics' shares. Their forecasts range from $26.00 to $44.00. On average, they expect Allogene Therapeutics' stock price to reach $33.11 in the next twelve months. This suggests a possible upside of 75.5% from the stock's current price. View analysts' price targets for Allogene Therapeutics. Has Allogene Therapeutics been receiving favorable news coverage? News stories about ALLO stock have been trending negative on Tuesday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allogene Therapeutics earned a news impact score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAllogene Therapeutics. Who are some of Allogene Therapeutics' key competitors? Some companies that are related to Allogene Therapeutics include Moderna (MRNA), Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD) and bluebird bio (BLUE). What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include Bristol-Myers Squibb (BMY), Crispr Therapeutics (CRSP), Amarin (AMRN), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Aduro BioTech (ADRO), Agile Therapeutics (AGRX), bluebird bio (BLUE), Editas Medicine (EDIT) and Nabriva Therapeutics (NBRV). Who are Allogene Therapeutics' key executives? Allogene Therapeutics' management team includes the following people: Mr. Joshua A. Kazam, Co-Founder & Director (Age 42)Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS, Co-Founder & Exec. Chairman (Age 70)Dr. David D. Chang M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 59)Dr. Eric Thomas Schmidt Ph.D., Chief Financial Officer (Age 51)Dr. Alison Moore Ph.D., Chief Technical Officer (Age 52) When did Allogene Therapeutics IPO? (ALLO) raised $272 million in an initial public offering on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO. What is Allogene Therapeutics' stock symbol? Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO." How do I buy shares of Allogene Therapeutics? Shares of ALLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Allogene Therapeutics' stock price today? One share of ALLO stock can currently be purchased for approximately $18.87. How big of a company is Allogene Therapeutics? Allogene Therapeutics has a market capitalization of $2.36 billion. The company earns $-184,590,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. Allogene Therapeutics employs 122 workers across the globe. View additional information about Allogene Therapeutics. What is Allogene Therapeutics' official website? The official website for Allogene Therapeutics is http://www.allogene.com/. How can I contact Allogene Therapeutics? Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-457-2700 or via email at [email protected] MarketBeat Community Rating for Allogene Therapeutics (NASDAQ ALLO)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 229 (Vote Underperform)Total Votes: 418MarketBeat's community ratings are surveys of what our community members think about Allogene Therapeutics and other stocks. Vote "Outperform" if you believe ALLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALLO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: What are the risks of holding treasury bonds?
